Performulation Studies In Sustained Release Development with Experimental Insights into Drug Polymer Incompatibility

Abstract

Preformulation studies are crucial to formulation development because they offer crucial details regarding a drug’s physicochemical and compatibility characteristics. In order to create a sustained release bead formulation that would prolong drug release and enhance patient compliance, the current study was conducted on molnupiravir. A controlled release system is necessary for molnupiravir, an antiviral medication with a short half-life, to maintain a constant plasma concentration and minimize frequent dosing. Solubility analysis, partition coefficient determination, melting point, drug stability, and organoleptic evaluation were among the preformulation studies carried out. FTIR spectroscopy techniques were used to evaluate drug-polymer compatibility studies in order to detect any potential interactions. The findings showed no appreciable alterations in the distinctive peaks, demonstrating that molnupiravir is compatible with the chosen polymers, including sodium, ethyl cellulose, and HPMC K4M.

Keywords

Introduction

The purpose of drug delivery systems is to deliver therapeutic agents to particular body locations at a predetermined rate and duration in order to produce the best possible therapeutic results. Enhancing patient compliance, lowering dosage frequency, minimizing side effects, and increasing bioavailability are the objectives of a contemporary Novel Drug Delivery System (NDDS). The capacity of advanced delivery systems, such as controlled release or sustained release formulations, to sustain consistent plasma concentrations and extended therapeutic action has made them more significant. 2. . Sustained Release Formulations Are Needed: Multiple daily doses are necessary because conventional dosage forms frequently cause fluctuations in plasma drug levels. To solve this issue, sustained release formulations are created, which release the medication over a longer period of time at a regulated rate. Benefits include: Preserving consistent therapeutic levels; lowering the frequency of doses; improving patient compliance; and minimizing adverse effects.

METHOD:

Supplies And Methods: -

SUPPLIES: 1. Molnupiravir, the medication 2. Alginate made of sodium 3. 4. Ethanol. 5. EDTA. Chloride of calcium 6. HPMC 7. . Cellulose8 methyl carboxy cellulose. Procedures for propylene glycol: 1. Organoleptic Properties: Molnupiravir’s organoleptic studies include its overall appearance, including its color, nature, and odor. Were conducted and watched. 2. . Identification of Melting Point Range: The USP method was used to determine the melting point. A capillary tube that was sealed was filled with a small amount of molnupiravir. The melting point apparatus was positioned over the tube. Gradually raising the device’s temperature allowed for the monitoring of the temperature at which molnupiravir began to melt as well as the temperature at which the entire medication melted. The “open capillary method” is another name for this approach. 3. . Investigation of drug-polymer interaction (FTIR): Fourier transformed infrared spectroscopy was used for FTIR spectroscopy. The wave numbers for the drug and polymer mixture scan ranged from 3971point 35 to 678point 36.

Preparation of molnupiravir microbeads:

Method Used:

Ionotropic – gelation technique Microbeads of molnupiravir were prepared using sodium alginate, sodium carboxy methyl cellulose, HPMC, EDTA and calcium chloride. Weighed quantity of drug and polymer were added to 100ml of sodium alginate solution with stirring about 300 rpm. The resultant solution was added drop wise to 100 ml of calcium chloride solution under constant stirring using 12.7gauge needle syringe. The obtained microbeads were filtered and then dried for 6hrs.

Drug profile:

1 Drug name: Molnupiravir2 IUPAC name: [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate3 Structural formula: 4 Empirical formula: C13H19N3O75 Molecular weight: 329.3g/mol6 Class: broad spectrum anti-viral7 Category: Anti-viral agent8 Mechanism of action: Molnupiravir prevents the spread of infection by causing widespread mutations in the replication of viral RNA by RNA-directed RNA polymerase. It undergoes metabolism to produce β-D-N 4-Hydroxycytidine 5′-triphosphate, also known as EIDD-1931 5′-triphosphate or NHC-TP, a ribonucleoside analogue that resembles cytidine. NHC-TP is incorporated into freshly synthesized RNA by the virus’s enzyme during replication rather than actual cytidine. Side effects: nausea, diarrhea, and dizziness; 11 uses; COVID-19; POLYMER PROFILE: -1; 9pH1.5-2.510. The structural formula for sodium alginate is: Sodium alginate, Natrii alginas. Hydropropyl Propyl Methyl Celluse, Hypromellose is the name of HPME.

DISCUSSION:

To learn more about Mol crystalline form, which is white to off-white nupiravir’s physicochemical characteristics and compatibility with particular polymers, preformulation studies were conducted. The drug’s and odorless, was confirmed by the organoleptic evaluation. According to the measured partition coefficient (log P = -0.30), molnupiravir is hydrophilic, which supports the necessity of a sustained release system to extend its therapeutic effect. FTIR analysis of drug and polymer mixtures revealed no discernible changes in characteristic peaks, indicating that there was no chemical interaction and that the mixtures were compatible with polymers like sodium alginate, ethyl cellulose, and HPMC K4M. These results indicated that the polymers could be used to formulate Molnupiravir beads with sustained release that were made using the ionotropic gelation method. According to the study’s findings, molnupiravir can be successfully combined with the chosen excipients to create a stable suspension.

SUMMARY AND CONCLUSION:

Molnupiravir’s physicochemical characteristics and compatibility with polymers for formulation of sustained release beads were assessed through preformulation studies. Confirming purity, the drug was discovered to be a white, odorless, crystalline powder with a melting point of 171 °C. In order to sustain extended drug levels, a sustained release system is required, as indicated by the partition coefficient (log P = -0.30), which indicated hydrophilic nature. The compatibility of Molnupiravir with polymers like HPMC K4M, EDTA, propylene glycol, and sodium alginate was confirmed by FTIR spectroscopy analysis, which revealed no appreciable changes in identifiable peaks. According to the reference study, the ionotropic gelation method produced uniform beads with good entrapment and controlled release. The investigation came to the conclusion that molnupiravir is physicochemically stable and compatible with specific polymers, which makes it appropriate for creating a sustained release bead formulation.

RESULT:

Solubility: It was ascertained using the method specified in the material and equipment section of the preformulation. The following table provides an illustration of the findings.  1: Molnupiravir microbead solubility: Test Specification Outcome Solubility: Water and ethanol soluble, insoluble in 2-propanal Compiled (as specified) Melting point: Melting point was ascertained using a melting point apparatus. The following table provides an illustration of the findings. 2: Molnupiravir’s melting point: Material: Melting pointResult: Molnupiravir171 0CCompiles (per specification) Drug-polymer interaction (FTIR) study: IN-VITRO Dissolution graph of Molnupiravir: Partition Coefficient: The shake flask method was used to determine it in accordance with the protocol. PHASE CONCENTRATION Aqueous Layer 42ug/mln-octanol Layer 21ug/mlCALCULATION is an example of the results.

REFERENCES

1. Phanideepthi V, Srinivasakumari CH, Reddy GV, Ruchitha K, Dhandapani MS. Formulation and evaluation of sustained release Molnupiravir enclosed microbeads. Int J Novel Res Dev (IJNRD). 2022;7(7):826–856.
2. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. 3rd ed. Philadelphia: Lea & Febiger; 1986.
3. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics – The Design and Manufacture of Medicines. 5th ed. Edinburgh: Churchill Livingstone Elsevier; 2018.
4. Ansel HC, Allen LV, Popovich NG. Pharmaceutical Dosage Forms and Drug Delivery Systems. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
5. Banker GS, Rhodes CT. Modern Pharmaceutics. 4th ed. New York: Marcel Dekker Inc.; 2002.
6. Gierszewska MJ, Ostrowska-Czubenko J, Chrzanowska E. pH-responsive chitosan/alginate polyelectrolyte complex membranes reinforced by tripolyphosphate. Eur Polym J. 2018;101:282–290.
7. Kota RK, Gande S. Development and characterization of alginate microspheres containing Olmesartan by ionotropic gelation method. Int J Pharm Sci Drug Res. 2018;10(4):335–341.
8. Bilal M, Rasheed T, Iqbal HMN, Li C, Hu H, Zhang X. Development of silver nanoparticles loaded chitosan–alginate constructs with biomedical potentialities. Int J Biol Macromol. 2017;105(1):393–400.
9. Winter ME. Basic Clinical Pharmacokinetics. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2017.
10. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Pharmacology. 9thed. London: Elsevier; 2020.